West Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

West Syndrome Market Outlook

Thelansis’s “West Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential West Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

West Syndrome Overview

West syndrome, also known as Infantile spasms, is a severe neurological disorder that affects infants and young children, characterized by early onset seizures, usually between 4-7 months of age, which can be flexor, extensor or flexor-extensor spasms, abnormal brain activity seen on an EEG and a poor prognosis for seizure control and intellectual development. The cause of West syndrome can be prenatal, perinatal, or postnatal. It can be classified as symptomatic groups that are considered the consequences of a known or suspected central nervous system disorder. Cryptogenic groups are presumed to be symptomatic, but the etiology is not known. Idiopathic forms, having no underlying cause other than a possible hereditary predisposition, are not recognized for West syndrome in the current International Classification. Other conditions that may be considered in the diagnosis of West syndrome include epilepsy with mental retardation, other epileptic and epileptiform encephalopathies, benign myoclonus of early infancy, and myoclonic-astatic epilepsy. The outlook for infants with West syndrome is poor, with only 14% of infants with symptomatic West syndrome having normal or borderline-normal cognitive development compared with 28-50% of infants with idiopathic infantile spasms. Some factors such as idiopathic or cryptogenic etiology, the onset of seizures after four months, absence of atypical spasms and partial seizures, absence of asymmetrical EEG abnormalities, early treatment, and an excellent response to treatment can predict a more favourable outcome. Infants with symptomatic infantile spasms are more likely to develop autism spectrum disorders than those with cryptogenic or idiopathic spasms. Steroids and anti-seizure medications are the most commonly used treatments, with the steroid ACTH sometimes being injected into the muscles.

• The incidence rate of infantile spasms in the USA is estimated to be 2.5-6.0 cases per 10,000 live births. Its prevalence rate is 1.5-2.0 cases per 10,000 children aged ten years or younger.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: